ArticleJournal of cellular and molecular medicine2025
Jiangtang Tiaozhi Formula Relieves HFD-Induced Obesity Related Type 2 Diabetes by Inhibiting the cGAS-STING Pathway.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Jiangtang Tiaozhi Formula Relieves HFD-Induced Obesity Related Type 2 Diabetes by Inhibiting the cGAS-STING Pathway.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Jiangtang Tiaozhi Formula (JTTZF), a traditional Chinese medicine (TCM) prescription, has been widely used clinically for obesity-related type 2 diabetes (T2D) for many years that can clear heat, release turbidity, open up stagnation and unblock meridians. Several previous clinical studies have demonstrated its effectiveness in decreasing glucose and lipid metabolism disorders, weight loss, and improving chronic inflammation and insulin resistance (IR); however, the exact pathways through which it influences obesity-related T2D require further investigation. This study aims to establish a systematic approach to the pharmacological basis of JTTZF and assess the therapeutic efficacy and its potential mechanisms of JTTZF in ameliorating obesity-related T2D induced by high-fat diet (HFD). Using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS), we identified JTTZF metabolites. Obesity-related diabetic models were established in both mice and zebrafish. The treatment effects were evaluated through haematoxylin and eosin (H&E) and oil Red O (ORO) staining, transmission electron microscopy and assessment of glucose/lipid metabolism indicators. Finally, the specific molecular mechanism underlying JTTZF's efficacy against this condition was comprehensively analysed via in vivo experimental verification. UHPLC-MS/MS identified 371 compounds in JTTZF, with 14 prototype constituents (e.g., demethyleneberberine, epiberberine) absorbed in the liver, linked to anti-diabetic activity. In HFD-induced zebrafish and C57BL/6 mice models, JTTZF significantly ameliorated glucose and lipid metabolic disorders. Histopathological and ultrastructural analyses revealed attenuated hepatic steatosis, reduced lipid droplets and restored mitochondrial integrity. JTTZF also suppressed hepatic inflammation by down-regulating proinflammatory cytokines. Mechanistically, JTTZF inhibited the cyclic GMP-AMP synthase (cGAS)-stimulator of IFN genes (STING) pathway, decreasing phosphorylation of cyclic GMP-AMP synthase-stimulator of type I interferon genes (TBK1) and nuclear factor-κB (NF-κB), while STING inhibitor C-176 and Metformin also displayed similar effects. These findings suggest that JTTZF is a therapeutic agent in inhibiting STING-restored metabolic homeostasis for the management of obesity-related T2D via the cGAS-STING/TBK1/NF-κB pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.